Ultrafast Magnetic Resonance Imaging for Iron Quantification in Thalassemia Participants in the Developing World
2016; Lippincott Williams & Wilkins; Volume: 134; Issue: 5 Linguagem: Inglês
10.1161/circulationaha.116.022803
ISSN1524-4539
AutoresAmna Abdel‐Gadir, Yongkasem Vorasettakarnkij, Hataichanok Ngamkasem, Sabrina Nordin, Emmanuel Ako, Monravee Tumkosit, Pranee Sucharitchan, Noppacharn Uaprasert, Peter Kellman, Stefan K. Piechnik, Marianna Fontana, Juliano Lara Fernandes, Charlotte Manisty, Mark Westwood, John B. Porter, John M. Walker, James Moon,
Tópico(s)Prenatal Screening and Diagnostics
ResumoHomeCirculationVol. 134, No. 5Ultrafast Magnetic Resonance Imaging for Iron Quantification in Thalassemia Participants in the Developing World Open AccessLetterPDF/EPUBAboutView PDFView EPUBSections ToolsAdd to favoritesDownload citationsTrack citationsPermissions ShareShare onFacebookTwitterLinked InMendeleyReddit Jump toOpen AccessLetterPDF/EPUBUltrafast Magnetic Resonance Imaging for Iron Quantification in Thalassemia Participants in the Developing WorldThe TIC-TOC Study (Thailand and UK International Collaboration in Thalassaemia Optimising Ultrafast CMR) Amna Abdel-Gadir, MRCP, Yongkasem Vorasettakarnkij, MD, Hataichanok Ngamkasem, MD, Sabrina Nordin, MRCP, Emmanuel A. Ako, MRCP, Monravee Tumkosit, MD, Pranee Sucharitchan, MD, Noppacharn Uaprasert, MD, Peter Kellman, PhD, Stefan K. Piechnik, PhD, Marianna Fontana, PhD, Juliano L. Fernandes, PhD, Charlotte Manisty, PhD, Mark Westwood, MD, John B. Porter, MD, J. Malcolm Walker, MD and James C. Moon, MD Amna Abdel-GadirAmna Abdel-Gadir From Institute of Cardiovascular Science, University College London, UK (A.A.-G., S.N., E.A.A., M.F., C.M., J.M.W., J.C.M.);Barts Heart Centre, London, UK (A.A.-G., S.N., E.A.A., C.M., M.W., J.C.M.); Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand (Y.V., M.T., P.S., N.U.); King Chulalongkorn Memorial Hospital, Bangkok, Thailand (Y.V., M.T., P.S., N.U.); Queen Savang Vadhana Memorial Hospital, Sriracha, Thailand (H.N.); Medical Signal and Image Processing Program, National Heart, Lung, and Blood Institute, Bethesda, MD (P.K.); University of Oxford Centre for Clinical Magnetic Resonance Research, Radcliffe Department of Medicine, Division of Cardiovascular Medicine, UK (S.K.P.); National Amyloidosis Centre, Royal Free Hospital, London, UK (M.F.); Cardiovascular Imaging Center, Jose Michel Kalaf Research Institute, Sao Paulo, Brazil (J.L.F.); Haematology Department, University College London Hospitals, UK (J.B.P.); and Hatter Cardiovascular Institute, University College Hospital, London, UK (J.M.W.). , Yongkasem VorasettakarnkijYongkasem Vorasettakarnkij From Institute of Cardiovascular Science, University College London, UK (A.A.-G., S.N., E.A.A., M.F., C.M., J.M.W., J.C.M.);Barts Heart Centre, London, UK (A.A.-G., S.N., E.A.A., C.M., M.W., J.C.M.); Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand (Y.V., M.T., P.S., N.U.); King Chulalongkorn Memorial Hospital, Bangkok, Thailand (Y.V., M.T., P.S., N.U.); Queen Savang Vadhana Memorial Hospital, Sriracha, Thailand (H.N.); Medical Signal and Image Processing Program, National Heart, Lung, and Blood Institute, Bethesda, MD (P.K.); University of Oxford Centre for Clinical Magnetic Resonance Research, Radcliffe Department of Medicine, Division of Cardiovascular Medicine, UK (S.K.P.); National Amyloidosis Centre, Royal Free Hospital, London, UK (M.F.); Cardiovascular Imaging Center, Jose Michel Kalaf Research Institute, Sao Paulo, Brazil (J.L.F.); Haematology Department, University College London Hospitals, UK (J.B.P.); and Hatter Cardiovascular Institute, University College Hospital, London, UK (J.M.W.). , Hataichanok NgamkasemHataichanok Ngamkasem From Institute of Cardiovascular Science, University College London, UK (A.A.-G., S.N., E.A.A., M.F., C.M., J.M.W., J.C.M.);Barts Heart Centre, London, UK (A.A.-G., S.N., E.A.A., C.M., M.W., J.C.M.); Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand (Y.V., M.T., P.S., N.U.); King Chulalongkorn Memorial Hospital, Bangkok, Thailand (Y.V., M.T., P.S., N.U.); Queen Savang Vadhana Memorial Hospital, Sriracha, Thailand (H.N.); Medical Signal and Image Processing Program, National Heart, Lung, and Blood Institute, Bethesda, MD (P.K.); University of Oxford Centre for Clinical Magnetic Resonance Research, Radcliffe Department of Medicine, Division of Cardiovascular Medicine, UK (S.K.P.); National Amyloidosis Centre, Royal Free Hospital, London, UK (M.F.); Cardiovascular Imaging Center, Jose Michel Kalaf Research Institute, Sao Paulo, Brazil (J.L.F.); Haematology Department, University College London Hospitals, UK (J.B.P.); and Hatter Cardiovascular Institute, University College Hospital, London, UK (J.M.W.). , Sabrina NordinSabrina Nordin From Institute of Cardiovascular Science, University College London, UK (A.A.-G., S.N., E.A.A., M.F., C.M., J.M.W., J.C.M.);Barts Heart Centre, London, UK (A.A.-G., S.N., E.A.A., C.M., M.W., J.C.M.); Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand (Y.V., M.T., P.S., N.U.); King Chulalongkorn Memorial Hospital, Bangkok, Thailand (Y.V., M.T., P.S., N.U.); Queen Savang Vadhana Memorial Hospital, Sriracha, Thailand (H.N.); Medical Signal and Image Processing Program, National Heart, Lung, and Blood Institute, Bethesda, MD (P.K.); University of Oxford Centre for Clinical Magnetic Resonance Research, Radcliffe Department of Medicine, Division of Cardiovascular Medicine, UK (S.K.P.); National Amyloidosis Centre, Royal Free Hospital, London, UK (M.F.); Cardiovascular Imaging Center, Jose Michel Kalaf Research Institute, Sao Paulo, Brazil (J.L.F.); Haematology Department, University College London Hospitals, UK (J.B.P.); and Hatter Cardiovascular Institute, University College Hospital, London, UK (J.M.W.). , Emmanuel A. AkoEmmanuel A. Ako From Institute of Cardiovascular Science, University College London, UK (A.A.-G., S.N., E.A.A., M.F., C.M., J.M.W., J.C.M.);Barts Heart Centre, London, UK (A.A.-G., S.N., E.A.A., C.M., M.W., J.C.M.); Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand (Y.V., M.T., P.S., N.U.); King Chulalongkorn Memorial Hospital, Bangkok, Thailand (Y.V., M.T., P.S., N.U.); Queen Savang Vadhana Memorial Hospital, Sriracha, Thailand (H.N.); Medical Signal and Image Processing Program, National Heart, Lung, and Blood Institute, Bethesda, MD (P.K.); University of Oxford Centre for Clinical Magnetic Resonance Research, Radcliffe Department of Medicine, Division of Cardiovascular Medicine, UK (S.K.P.); National Amyloidosis Centre, Royal Free Hospital, London, UK (M.F.); Cardiovascular Imaging Center, Jose Michel Kalaf Research Institute, Sao Paulo, Brazil (J.L.F.); Haematology Department, University College London Hospitals, UK (J.B.P.); and Hatter Cardiovascular Institute, University College Hospital, London, UK (J.M.W.). , Monravee TumkositMonravee Tumkosit From Institute of Cardiovascular Science, University College London, UK (A.A.-G., S.N., E.A.A., M.F., C.M., J.M.W., J.C.M.);Barts Heart Centre, London, UK (A.A.-G., S.N., E.A.A., C.M., M.W., J.C.M.); Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand (Y.V., M.T., P.S., N.U.); King Chulalongkorn Memorial Hospital, Bangkok, Thailand (Y.V., M.T., P.S., N.U.); Queen Savang Vadhana Memorial Hospital, Sriracha, Thailand (H.N.); Medical Signal and Image Processing Program, National Heart, Lung, and Blood Institute, Bethesda, MD (P.K.); University of Oxford Centre for Clinical Magnetic Resonance Research, Radcliffe Department of Medicine, Division of Cardiovascular Medicine, UK (S.K.P.); National Amyloidosis Centre, Royal Free Hospital, London, UK (M.F.); Cardiovascular Imaging Center, Jose Michel Kalaf Research Institute, Sao Paulo, Brazil (J.L.F.); Haematology Department, University College London Hospitals, UK (J.B.P.); and Hatter Cardiovascular Institute, University College Hospital, London, UK (J.M.W.). , Pranee SucharitchanPranee Sucharitchan From Institute of Cardiovascular Science, University College London, UK (A.A.-G., S.N., E.A.A., M.F., C.M., J.M.W., J.C.M.);Barts Heart Centre, London, UK (A.A.-G., S.N., E.A.A., C.M., M.W., J.C.M.); Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand (Y.V., M.T., P.S., N.U.); King Chulalongkorn Memorial Hospital, Bangkok, Thailand (Y.V., M.T., P.S., N.U.); Queen Savang Vadhana Memorial Hospital, Sriracha, Thailand (H.N.); Medical Signal and Image Processing Program, National Heart, Lung, and Blood Institute, Bethesda, MD (P.K.); University of Oxford Centre for Clinical Magnetic Resonance Research, Radcliffe Department of Medicine, Division of Cardiovascular Medicine, UK (S.K.P.); National Amyloidosis Centre, Royal Free Hospital, London, UK (M.F.); Cardiovascular Imaging Center, Jose Michel Kalaf Research Institute, Sao Paulo, Brazil (J.L.F.); Haematology Department, University College London Hospitals, UK (J.B.P.); and Hatter Cardiovascular Institute, University College Hospital, London, UK (J.M.W.). , Noppacharn UaprasertNoppacharn Uaprasert From Institute of Cardiovascular Science, University College London, UK (A.A.-G., S.N., E.A.A., M.F., C.M., J.M.W., J.C.M.);Barts Heart Centre, London, UK (A.A.-G., S.N., E.A.A., C.M., M.W., J.C.M.); Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand (Y.V., M.T., P.S., N.U.); King Chulalongkorn Memorial Hospital, Bangkok, Thailand (Y.V., M.T., P.S., N.U.); Queen Savang Vadhana Memorial Hospital, Sriracha, Thailand (H.N.); Medical Signal and Image Processing Program, National Heart, Lung, and Blood Institute, Bethesda, MD (P.K.); University of Oxford Centre for Clinical Magnetic Resonance Research, Radcliffe Department of Medicine, Division of Cardiovascular Medicine, UK (S.K.P.); National Amyloidosis Centre, Royal Free Hospital, London, UK (M.F.); Cardiovascular Imaging Center, Jose Michel Kalaf Research Institute, Sao Paulo, Brazil (J.L.F.); Haematology Department, University College London Hospitals, UK (J.B.P.); and Hatter Cardiovascular Institute, University College Hospital, London, UK (J.M.W.). , Peter KellmanPeter Kellman From Institute of Cardiovascular Science, University College London, UK (A.A.-G., S.N., E.A.A., M.F., C.M., J.M.W., J.C.M.);Barts Heart Centre, London, UK (A.A.-G., S.N., E.A.A., C.M., M.W., J.C.M.); Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand (Y.V., M.T., P.S., N.U.); King Chulalongkorn Memorial Hospital, Bangkok, Thailand (Y.V., M.T., P.S., N.U.); Queen Savang Vadhana Memorial Hospital, Sriracha, Thailand (H.N.); Medical Signal and Image Processing Program, National Heart, Lung, and Blood Institute, Bethesda, MD (P.K.); University of Oxford Centre for Clinical Magnetic Resonance Research, Radcliffe Department of Medicine, Division of Cardiovascular Medicine, UK (S.K.P.); National Amyloidosis Centre, Royal Free Hospital, London, UK (M.F.); Cardiovascular Imaging Center, Jose Michel Kalaf Research Institute, Sao Paulo, Brazil (J.L.F.); Haematology Department, University College London Hospitals, UK (J.B.P.); and Hatter Cardiovascular Institute, University College Hospital, London, UK (J.M.W.). , Stefan K. PiechnikStefan K. Piechnik From Institute of Cardiovascular Science, University College London, UK (A.A.-G., S.N., E.A.A., M.F., C.M., J.M.W., J.C.M.);Barts Heart Centre, London, UK (A.A.-G., S.N., E.A.A., C.M., M.W., J.C.M.); Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand (Y.V., M.T., P.S., N.U.); King Chulalongkorn Memorial Hospital, Bangkok, Thailand (Y.V., M.T., P.S., N.U.); Queen Savang Vadhana Memorial Hospital, Sriracha, Thailand (H.N.); Medical Signal and Image Processing Program, National Heart, Lung, and Blood Institute, Bethesda, MD (P.K.); University of Oxford Centre for Clinical Magnetic Resonance Research, Radcliffe Department of Medicine, Division of Cardiovascular Medicine, UK (S.K.P.); National Amyloidosis Centre, Royal Free Hospital, London, UK (M.F.); Cardiovascular Imaging Center, Jose Michel Kalaf Research Institute, Sao Paulo, Brazil (J.L.F.); Haematology Department, University College London Hospitals, UK (J.B.P.); and Hatter Cardiovascular Institute, University College Hospital, London, UK (J.M.W.). , Marianna FontanaMarianna Fontana From Institute of Cardiovascular Science, University College London, UK (A.A.-G., S.N., E.A.A., M.F., C.M., J.M.W., J.C.M.);Barts Heart Centre, London, UK (A.A.-G., S.N., E.A.A., C.M., M.W., J.C.M.); Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand (Y.V., M.T., P.S., N.U.); King Chulalongkorn Memorial Hospital, Bangkok, Thailand (Y.V., M.T., P.S., N.U.); Queen Savang Vadhana Memorial Hospital, Sriracha, Thailand (H.N.); Medical Signal and Image Processing Program, National Heart, Lung, and Blood Institute, Bethesda, MD (P.K.); University of Oxford Centre for Clinical Magnetic Resonance Research, Radcliffe Department of Medicine, Division of Cardiovascular Medicine, UK (S.K.P.); National Amyloidosis Centre, Royal Free Hospital, London, UK (M.F.); Cardiovascular Imaging Center, Jose Michel Kalaf Research Institute, Sao Paulo, Brazil (J.L.F.); Haematology Department, University College London Hospitals, UK (J.B.P.); and Hatter Cardiovascular Institute, University College Hospital, London, UK (J.M.W.). , Juliano L. FernandesJuliano L. Fernandes From Institute of Cardiovascular Science, University College London, UK (A.A.-G., S.N., E.A.A., M.F., C.M., J.M.W., J.C.M.);Barts Heart Centre, London, UK (A.A.-G., S.N., E.A.A., C.M., M.W., J.C.M.); Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand (Y.V., M.T., P.S., N.U.); King Chulalongkorn Memorial Hospital, Bangkok, Thailand (Y.V., M.T., P.S., N.U.); Queen Savang Vadhana Memorial Hospital, Sriracha, Thailand (H.N.); Medical Signal and Image Processing Program, National Heart, Lung, and Blood Institute, Bethesda, MD (P.K.); University of Oxford Centre for Clinical Magnetic Resonance Research, Radcliffe Department of Medicine, Division of Cardiovascular Medicine, UK (S.K.P.); National Amyloidosis Centre, Royal Free Hospital, London, UK (M.F.); Cardiovascular Imaging Center, Jose Michel Kalaf Research Institute, Sao Paulo, Brazil (J.L.F.); Haematology Department, University College London Hospitals, UK (J.B.P.); and Hatter Cardiovascular Institute, University College Hospital, London, UK (J.M.W.). , Charlotte ManistyCharlotte Manisty From Institute of Cardiovascular Science, University College London, UK (A.A.-G., S.N., E.A.A., M.F., C.M., J.M.W., J.C.M.);Barts Heart Centre, London, UK (A.A.-G., S.N., E.A.A., C.M., M.W., J.C.M.); Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand (Y.V., M.T., P.S., N.U.); King Chulalongkorn Memorial Hospital, Bangkok, Thailand (Y.V., M.T., P.S., N.U.); Queen Savang Vadhana Memorial Hospital, Sriracha, Thailand (H.N.); Medical Signal and Image Processing Program, National Heart, Lung, and Blood Institute, Bethesda, MD (P.K.); University of Oxford Centre for Clinical Magnetic Resonance Research, Radcliffe Department of Medicine, Division of Cardiovascular Medicine, UK (S.K.P.); National Amyloidosis Centre, Royal Free Hospital, London, UK (M.F.); Cardiovascular Imaging Center, Jose Michel Kalaf Research Institute, Sao Paulo, Brazil (J.L.F.); Haematology Department, University College London Hospitals, UK (J.B.P.); and Hatter Cardiovascular Institute, University College Hospital, London, UK (J.M.W.). , Mark WestwoodMark Westwood From Institute of Cardiovascular Science, University College London, UK (A.A.-G., S.N., E.A.A., M.F., C.M., J.M.W., J.C.M.);Barts Heart Centre, London, UK (A.A.-G., S.N., E.A.A., C.M., M.W., J.C.M.); Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand (Y.V., M.T., P.S., N.U.); King Chulalongkorn Memorial Hospital, Bangkok, Thailand (Y.V., M.T., P.S., N.U.); Queen Savang Vadhana Memorial Hospital, Sriracha, Thailand (H.N.); Medical Signal and Image Processing Program, National Heart, Lung, and Blood Institute, Bethesda, MD (P.K.); University of Oxford Centre for Clinical Magnetic Resonance Research, Radcliffe Department of Medicine, Division of Cardiovascular Medicine, UK (S.K.P.); National Amyloidosis Centre, Royal Free Hospital, London, UK (M.F.); Cardiovascular Imaging Center, Jose Michel Kalaf Research Institute, Sao Paulo, Brazil (J.L.F.); Haematology Department, University College London Hospitals, UK (J.B.P.); and Hatter Cardiovascular Institute, University College Hospital, London, UK (J.M.W.). , John B. PorterJohn B. Porter From Institute of Cardiovascular Science, University College London, UK (A.A.-G., S.N., E.A.A., M.F., C.M., J.M.W., J.C.M.);Barts Heart Centre, London, UK (A.A.-G., S.N., E.A.A., C.M., M.W., J.C.M.); Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand (Y.V., M.T., P.S., N.U.); King Chulalongkorn Memorial Hospital, Bangkok, Thailand (Y.V., M.T., P.S., N.U.); Queen Savang Vadhana Memorial Hospital, Sriracha, Thailand (H.N.); Medical Signal and Image Processing Program, National Heart, Lung, and Blood Institute, Bethesda, MD (P.K.); University of Oxford Centre for Clinical Magnetic Resonance Research, Radcliffe Department of Medicine, Division of Cardiovascular Medicine, UK (S.K.P.); National Amyloidosis Centre, Royal Free Hospital, London, UK (M.F.); Cardiovascular Imaging Center, Jose Michel Kalaf Research Institute, Sao Paulo, Brazil (J.L.F.); Haematology Department, University College London Hospitals, UK (J.B.P.); and Hatter Cardiovascular Institute, University College Hospital, London, UK (J.M.W.). , J. Malcolm WalkerJ. Malcolm Walker From Institute of Cardiovascular Science, University College London, UK (A.A.-G., S.N., E.A.A., M.F., C.M., J.M.W., J.C.M.);Barts Heart Centre, London, UK (A.A.-G., S.N., E.A.A., C.M., M.W., J.C.M.); Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand (Y.V., M.T., P.S., N.U.); King Chulalongkorn Memorial Hospital, Bangkok, Thailand (Y.V., M.T., P.S., N.U.); Queen Savang Vadhana Memorial Hospital, Sriracha, Thailand (H.N.); Medical Signal and Image Processing Program, National Heart, Lung, and Blood Institute, Bethesda, MD (P.K.); University of Oxford Centre for Clinical Magnetic Resonance Research, Radcliffe Department of Medicine, Division of Cardiovascular Medicine, UK (S.K.P.); National Amyloidosis Centre, Royal Free Hospital, London, UK (M.F.); Cardiovascular Imaging Center, Jose Michel Kalaf Research Institute, Sao Paulo, Brazil (J.L.F.); Haematology Department, University College London Hospitals, UK (J.B.P.); and Hatter Cardiovascular Institute, University College Hospital, London, UK (J.M.W.). and James C. MoonJames C. Moon From Institute of Cardiovascular Science, University College London, UK (A.A.-G., S.N., E.A.A., M.F., C.M., J.M.W., J.C.M.);Barts Heart Centre, London, UK (A.A.-G., S.N., E.A.A., C.M., M.W., J.C.M.); Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand (Y.V., M.T., P.S., N.U.); King Chulalongkorn Memorial Hospital, Bangkok, Thailand (Y.V., M.T., P.S., N.U.); Queen Savang Vadhana Memorial Hospital, Sriracha, Thailand (H.N.); Medical Signal and Image Processing Program, National Heart, Lung, and Blood Institute, Bethesda, MD (P.K.); University of Oxford Centre for Clinical Magnetic Resonance Research, Radcliffe Department of Medicine, Division of Cardiovascular Medicine, UK (S.K.P.); National Amyloidosis Centre, Royal Free Hospital, London, UK (M.F.); Cardiovascular Imaging Center, Jose Michel Kalaf Research Institute, Sao Paulo, Brazil (J.L.F.); Haematology Department, University College London Hospitals, UK (J.B.P.); and Hatter Cardiovascular Institute, University College Hospital, London, UK (J.M.W.). Originally published2 Aug 2016https://doi.org/10.1161/CIRCULATIONAHA.116.022803Circulation. 2016;134:432–434Thalassemia is the most common monogenetic disorder worldwide, with 60 000 infants with thalassemia major born annually.1 Survival often depends on regular blood transfusions to correct anemia and to reduce ineffective erythropoiesis, but these transfusions can result in iron overload and organ failure unless chelation therapy is undertaken. Serum ferritin levels continue to be used as a guide to chelation but are unreliable, and the availability of cardiovascular magnetic resonance (CMR) T2* imaging has transformed patient management by allowing organ-specific quantification of iron content.2,3Countries with a high prevalence of thalassemia major have CMR, but magnet time is expensive and analytic expertise lacking. The aim of TIC-TOC (Thailand and UK International Collaboration in Thalassaemia Optimising Ultrafast CMR) was to investigate whether ultrafast CMR mapping could provide reliable immediate diagnoses of heart and liver iron content, eliminating the need for complex analysis, thus reducing costs to a level within local resources. The research received approval by the Institutional Review Board of the Faculty of Medicine at Chulalongkorn University. All participants provided written informed consent.One hundred participants with thalassemia major were recruited by the local support group at the King Chulalongkorn Memorial Hospital in Bangkok, Thailand. Eleven healthy volunteers not on cardio-active medication were recruited through local hospital advertising to confirm normal ranges. All participants underwent magnetic resonance imaging scans with a 1.5-T scanner (Aera, Siemens) calibrated with the T1MES (T1 Mapping and ECV Standardisation in CMR) phantom.4 The scan consisted of 10 breath holds: localizer and pilot images, myocardial and liver T2* and T1 mapping, anatomic half-Fourier acquisition single-shot turbo spin echo stack, and long-axis left ventricular steady-state free-precession cines with an optional short-axis cine stack (2 breath holds) if abnormal, but none were. Both modified look-locker inversion recovery (MOLLI) and shortened MOLLI (MyoMaps, Siemens) T1 mapping sequences were implemented. T2* and native T1 maps were performed on the same mid left ventricular short-axis slice. The black-blood T2* sequence consisted of 8 or 12 echoes (2.68–20.11 milliseconds; 2.49-millisecond increments for the heart; 12 in the transverse plane for the liver; minimum echo time, 0.99 millisecond). Images were analyzed as they were acquired, providing assessment of myocardial and liver iron, function, and extracardiac anatomy.For the myocardial maps, a single septal region of interest was manually traced. For the liver T2* maps, a large region of interest was traced, avoiding vasculature. Liver T1 values were obtained from the myocardial short-axis images. The 11 healthy volunteers all had normal scans. The lower limit of normal for T1 was taken as 2 SD below the mean and 20 millisecond for myocardial T2*.2,3Ferritin and hemoglobin blood levels were measured. One-year average ferritin values were calculated from a minimum of 3 values per patient.Of the 100 participants invited, 97 were scanned; 2 participants were unwell and 1 patient consented but was claustrophobic (Table). Visual left ventricular function assessment on long-axis cines was normal in all participants, including those with cardiac iron. In total, including test-retest, 123 scans were performed in 2 days (12-hour working days). Mean scan duration was 8.3±2.4 minutes with complete analysis within 1 minute of the last image acquisition.Table. Participant Baseline CharacteristicsCharacteristicsValuen97Age, y34.1±12.1Sex, M/F31/66Height, m1.57±0.08Weight, kg50.7±9.2BSA, m21.48±0.16Chelation DFO, n13 DPO, n63 Deferasirox, n6 DFO+DPO, n5 DPO+deferasirox, n2 None, n8MRI scanning duration, min8.3±2.4Myocardial T2*, ms29.5±7.9Myocardial iron by T2* <20 ms (participant frequency, %)15 (15.5)Liver T2*, ms2.5±1.4Liver iron by T2* <6.3 ms (participant frequency, %)96 (98.9)Average ferritin, μg/L3533±2897Hemoglobin, g/dL8.03±1.24Average ferritin over 1 year. Data are presented as mean±SD when appropriate. BSA indicates body surface area; DFO desferrioxamine; DPO, deferiprone; and MRI, magnetic resonance imaging.Fifteen participants had myocardial iron loading by T2* (10 severe, 2 moderate, 3 mild). There was good correlation between myocardial T2* and T1 maps (T2* versus MOLLI, r2=0.81; T2* versus shortened MOLLI, r2=0.83; both P<0.0001). All participants with low myocardial iron T2* had low T1 values. Thirty participants with normal T2* had low T1 MOLLI values (<982 milliseconds). Ninety-six participants had liver iron by T2*(46 severe, 33 moderate, 17 mild); only 1 patient had a normal liver T2* value. Liver T2* mapping correlated with T1 mapping (T2* versus MOLLI, r2=0.33; T2* versus shortened MOLLI, r2=0.36; P<0.0001).There was a weak correlation between myocardial and liver T2* maps and mean ferritin values (r2=0.17 and r2=0.15, respectively; both P<0.0001). There was no correlation with ferritin in severe myocardial and liver iron.TIC-TOC demonstrated the clinical and economic advantages of ultrafast magnetic resonance imaging protocols, scanning 6 participants per hour for two 12-hour days, reducing scanning costs by a factor of ≈4. Mapping analysis took minimal training, required <1 minute, and was reliable (data not shown). Mapping revealed a 15% prevalence of abnormal cardiac iron content by T2* and 45% by T1. High liver iron was detected in 99%. This study has demonstrated that ultrafast scanning is achievable with the use of sequences available on commercially available CMRs and scanners. Thus, widespread adoption of this approach is feasible and currently being investigated by the Global-AID project, which is endeavoring to distribute this technology to multiple countries to confirm applicability and cost-effectiveness and to investigate potential changes in outcomes.Amna Abdel-Gadir, MRCP*Yongkasem Vorasettakarnkij, MD*Hataichanok Ngamkasem, MDSabrina Nordin, MRCPEmmanuel A. Ako, MRCPMonravee Tumkosit, MDPranee Sucharitchan, MDNoppacharn Uaprasert, MDPeter Kellman, PhDStefan K. Piechnik, PhDMarianna Fontana, PhDJuliano L. Fernandes, PhDCharlotte Manisty, PhDMark Westwood, MDJohn B. Porter, MDJ. Malcolm Walker, MDJames C. Moon, MDAcknowledgmentsWe thank the patients, staff, and Chulalongkorn Thalassemia Support Group for their valuable contributions. We wish to acknowledge Andreas Greiser from Siemens AG Healthcare Sector.Sources of FundingDr Abdel-Gadir is supported by the Rosetrees Trust and UK Thalassaemia Society. Drs Vorasettakarnkij, Ngamkasem, Tumkosit, Sucharitchan, and Uaprasert are supported by the Ratchadapiseksompotch Fund, Faculty of Medicine, Chulalongkorn University (grant RA58/058). Dr Porter is supported by the British Research Council. Dr Piechnik is supported by the National Institute for Health Research Oxford Biomedical Research Center based at The Oxford University Hospitals Trust at the University of Oxford. Drs Moon and Manisty are supported by the UK National Institute for Health Research Biomedical Research Center funding scheme.DisclosuresNone.Footnotes*Drs Abdel-Gadir and Vorasettakarnkij are joint first authors.The opinions expressed in this article are not necessarily those of the editors or of the American Heart Association.Circulation is available at http://circ.ahajournals.org.Correspondence to: Amna Abdel-Gadir, MRCP, Barts Heart Centre, London, UK EC1A 7BE. E-mail [email protected]References1. Higgs DR, Engel JD, Stamatoyannopoulos G. Thalassaemia.Lancet. 2012; 379:373–383. doi: 10.1016/S0140-6736(11)60283-3.CrossrefMedlineGoogle Scholar2. Anderson LJ, Holden S, Davis B, Prescott E, Charrier CC, Bunce NH, Firmin DN, Wonke B, Porter J, Walker JM, Pennell DJ. Cardiovascular T2-star (T2*) magnetic resonance for the early diagnosis of myocardial iron overload.Eur Heart J. 2001; 22:2171–2179.CrossrefMedlineGoogle Scholar3. Carpenter JP, He T, Kirk P, Roughton M, Anderson LJ, de Noronha SV, Sheppard MN, Porter JB, Walker JM, Wood JC, Galanello R, Forni G, Catani G, Matta G, Fucharoen S, Fleming A, House MJ, Black G, Firmin DN, St Pierre TG, Pennell DJ. On T2* magnetic resonance and cardiac iron.Circulation. 2011; 123:1519–1528. doi: 10.1161/CIRCULATIONAHA.110.007641.LinkGoogle Scholar4. Captur G, Gatehouse P, Kellman P, Heslinga FG, Keenan K, Bruehl R, Prothmann M, Graves MJ, Chiribiri A, Ittermann B, Pang W, Nezafat R, Salerno M, Moon JC. A T1 and ECV phantom for global T1 mapping quality assurance: the T1 Mapping and ECV Standardisation in CMR (T1MES) program.J CardiovascMagnReson. 2016; 18:1–3.Google Scholar Previous Back to top Next FiguresReferencesRelatedDetailsCited By Medina K, Abdel-Gadir A, Ganga K, Ojha V, Pratap S, Boubertakh R, McGrath L, Augusto J, Rikowski A, Mughal N, Khanna V, Seth T, Sharma S, Mahajan A, Bansal R, Srivastava P, Mahajan H, Mahajan V, Walker J, Seldon T, Ako E, Moon J and Walker J (2021) Use of rapid cardiac magnetic resonance imaging to guide chelation therapy in patients with transfusion-dependent thalassaemia in India: UMIMI study, European Heart Journal - Quality of Care and Clinical Outcomes, 10.1093/ehjqcco/qcab089, 8:3, (289-297), Online publication date: 5-May-2022. Blankstein R, Shaw L, Gulati M, Atalay M, Bax J, Calnon D, Dyke C, Ferencik M, Heitner J, Henry T, Hung J, Knuuti J, Lindner J, Phillips L, Raman S, Rao S, Rybicki F, Saraste A, Stainback R, Thompson R, Williamson E, Nieman K, Tremmel J, Woodard P, Di Carli M and Chandrashekhar Y (2022) Implications of the 2021 AHA/ACC/ASE/CHEST/SAEM/SCCT/SCMR Chest Pain Guideline for Cardiovascular Imaging, JACC: Cardiovascular Imaging, 10.1016/j.jcmg.2022.02.021, 15:5, (912-926), Online publication date: 1-May-2022. Bulluck H, Carberry J, Carrick D, McCartney P, Maznyczka A, Greenwood J, Maredia N, Chowdhary S, Gershlick A, Appleby C, Cotton J, Wragg A, Curzen N, McEntegart M, Petrie M, Eteiba H, Watkins S, Lindsay M, Mahrous A, Oldroyd K and Berry C (2022) A Noncontrast CMR Risk Score for Long-Term Risk Stratification in Reperfused ST-Segment Elevation Myocardial Infarction, JACC: Cardiovascular Imaging, 10.1016/j.jcmg.2021.08.006, 15:3, (431-440), Online publication date: 1-Mar-2022. Raman S (2022) Advancing population-scale access to high-value cardiovascular care: a roadmap for CMR and beyond, European Heart Journal, 10.1093/eurheartj/ehac079 Menacho K, Ramirez S, Perez A, Dragonetti L, Perez de Arenaza D, Katekaru D, Illatopa V, Munive S, Rodriguez B, Shimabukuro A, Cupe K, Bansal R, Bhargava V, Rodriguez I, Seraphim A, Knott K, Abdel-Gadir A, Guerrero S, Lazo M, Uscamaita D, Rivero M, Amaya N, Sharma S, Peix A, Treibel T, Manisty C, Mohiddin S, Litt H, Han Y, Fernandes J, Jacob R, Westwood M, Ntusi N, Herrey A, Walker J and Moon J (2022) Improving cardiovascular magnetic resonance access in low- and middle-income countries for cardiomyopathy assessment: rapid cardiovascular magnetic resonance, European Heart Journal, 10.1093/eurheartj/ehac035 Torlasco C, Castelletti S, Soranna D, Volpato V, Figliozzi S, Menacho K, Cernigliaro F, Zambon A, Kellman P, Moon J, Badano L and Parati G (2021) Effective Study: Development and Application of a Question‐Driven, Time‐Effective Cardiac Magnetic Resonance Scanning Protocol, Journal of the American Heart Association, 11:1, Online publication date: 4-Jan-2022. Ochs M, Kajzar I, Salatzki J, Ochs A, Riffel J, Osman N, Katus H and Friedrich M (2021) Hyperventilation/Breath-Hold Maneuver to Detect Myocardial Ischemia by Strain-Encoded CMR, JACC: Cardiovascular Imaging, 10.1016/j.jcmg.2021.02.022, 14:10, (1932-1944), Online publication date: 1-Oct-2021. Menacho Medina K, Seraphim A, Katekaru D, Abdel-Gadir A, Han Y, Westwood M, Walker J, Moon J and Herrey A (2021) Noninvasive rapid cardiac magnetic resonance for the assessment of cardiomyopathies in low-middle income countries, Expert Review of Cardiovascular Therapy, 10.1080/14779072.2021.1915130, 19:5, (387-398), Online publication date: 4-May-2021. Golpayegani M, Akramipour R and Fattahi N (2021) Sensitive determination of deferasirox in blood of patients with thalassemia using dispersive liquid-liquid microextraction based on solidification of floating organic drop followed by HPLC–UV, Journal of Pharmaceutical and Biomedical Analysis, 10.1016/j.jpba.2020.113735, 193, (113735), Online publication date: 1-Jan-2021. Menacho-Medina K, Ntusi N, Moon J, Walker J and Jacob R (2020) Rapid Cardiac MRI Protocols: Feasibility and Potential Applications, Current Radiology Reports, 10.1007/s40134-020-0344-6, 8:2, Online publication date: 1-Feb-2020. Halliday B and Pennell D (2019) Cardiovascular Magnetic Resonance to Guide and Monitor the Myocardial Response to Treatment, Circulation: Cardiovascular Imaging, 12:12, Online publication date: 1-Dec-2019. Menacho K, Abdel-Gadir A, Moon J and Fernandes J (2019) T2* Mapping Techniques, Magnetic Resonance Imaging Clinics of North America, 10.1016/j.mric.2019.04.008, 27:3, (439-451), Online publication date: 1-Aug-2019. Heiss R, Wiesmueller M, Treutlein C, Seuss H, Uder M, May M and Wuest W (2018) Cardiac T2 star mapping: standardized inline analysis of long and short axis at three identical 1.5 T MRI scanners, The International Journal of Cardiovascular Imaging, 10.1007/s10554-018-1503-1, 35:4, (695-702), Online publication date: 1-Apr-2019. Kramer C (2018) Potential for Rapid and Cost‐Effective Cardiac Magnetic Resonance in the Developing (and Developed) World, Journal of the American Heart Association, 7:17, Online publication date: 4-Sep-2018.Menacho K, Ramirez S, Segura P, Nordin S, Abdel‐Gadir A, Illatopa V, Bhuva A, Benedetti G, Boubertakh R, Abad P, Rodriguez B, Medina F, Treibel T, Westwood M, Fernandes J, Walker J, Litt H and Moon J (2018) INCA (Peru) Study: Impact of Non‐Invasive Cardiac Magnetic Resonance Assessment in the Developing World, Journal of the American Heart Association, 7:17, Online publication date: 4-Sep-2018. Fernandes J (2018) MRI for Iron Overload in Thalassemia, Hematology/Oncology Clinics of North America, 10.1016/j.hoc.2017.11.012, 32:2, (277-295), Online publication date: 1-Apr-2018. Li T, Cui Z, Wang Y, Yang W, Li D, Song Q, Sun L and Ding L (2018) A simple LC–MS/MS method for determination of deferasirox in human plasma: Troubleshooting of interference from ferric ion in method development and its application, Journal of Pharmaceutical and Biomedical Analysis, 10.1016/j.jpba.2017.12.052, 151, (145-150), Online publication date: 1-Mar-2018. Torlasco C, Cassinerio E, Roghi A, Faini A, Capecchi M, Abdel-Gadir A, Giannattasio C, Parati G, Moon J, Cappellini M, Pedrotti P and Bauer W (2018) Role of T1 mapping as a complementary tool to T2* for non-invasive cardiac iron overload assessment, PLOS ONE, 10.1371/journal.pone.0192890, 13:2, (e0192890) Krittayaphong R, Zhang S, Saiviroonporn P, Viprakasit V, Tanapibunpon P, Komoltri C and Wangworatrakul W (2017) Detection of cardiac iron overload with native magnetic resonance T1 and T2 mapping in patients with thalassemia, International Journal of Cardiology, 10.1016/j.ijcard.2017.06.100, 248, (421-426), Online publication date: 1-Dec-2017. August 2, 2016Vol 134, Issue 5 Advertisement Article InformationMetrics © 2016 The Authors.Circulation is published on behalf of the American Heart Association, Inc., by Wolters Kluwer. This is an open access article under the terms of the Creative Commons Attribution Non-Commercial-NoDervis License, which permits use, distribution, and reproduction in any medium, provided that the original work is properly cited, the use is noncommercial, and no modifications or adaptations are made.https://doi.org/10.1161/CIRCULATIONAHA.116.022803PMID: 27482005 Manuscript receivedApril 1, 2016Manuscript acceptedMay 19, 2016Originally publishedAugust 2, 2016 Keywordscardiomyopathiesdiagnosisiron overloadmagnetic resonance imagingPDF download Advertisement SubjectsCardiomyopathyMagnetic Resonance Imaging (MRI)
Referência(s)